| Current Price | $0.25 | Mkt Cap | $70.1M |
|---|---|---|---|
| Open | $0.26 | P/E Ratio | -2.69 |
| Prev. Close | $0.25 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.25 - $0.26 | Volume | 240,656 |
| 52-Wk Range | $0.21 - $0.73 | Avg. Daily Vol. | 989,095 |
The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases.
| Current Price | $0.25 | Mkt Cap | $70.1M |
|---|---|---|---|
| Open | $0.26 | P/E Ratio | -2.69 |
| Prev. Close | $0.25 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.25 - $0.26 | Volume | 240,656 |
| 52-Wk Range | $0.21 - $0.73 | Avg. Daily Vol. | 989,095 |
The best Bull and Bear pitches based on recency and number of recommendations.
ISR a small medical device company, is already FDA approved and holds the paten, on Cesium-131 brachytherapy. ISR potentially cures cancer with outstanding results. MD Anderson, named the best cancer hospital, in America is now using the cesium-131.… More
Read the most recent pitches from players about ISR.
Recs
Alacrity
(< 20)
Submitted: 9/2/2015 1:31:13 PM :
Start Price:
$1.46
NYSE MKT:ISR Score:
-219.78
ISR a small medical device company, is already FDA approved and holds the paten, on Cesium-131 brachytherapy. ISR potentially cures cancer with outstanding results. MD Anderson, named the best cancer hospital, in America is now using the cesium-131. MD Anderson will have the results on, November 7, 2015 . ISR earnings are on Sept 14, 2015, last quarter ISR beat the consensus. In May, CEO Dwight Babcock, commented on the small cell lung cancer result, the stock soared. A very negative press release was released by, Adam Feuerstein resulting in several law suits, the stock then plummeted. Given the outstanding results, of cesium 131 and the ability to cure cancer is a very positive indication this will soon be a winner. Thomson Reuters, just gave the stock a four star out of ten and expected price target of 25.00. I am long in ISR, and I am waiting for some very positive results.
Recs
JacksonFool805
(< 20)
Submitted: 5/13/2014 5:08:55 PM :
Start Price:
$2.35
NYSE MKT:ISR Score:
-231.64
They have a propriety cancer fighting treatment already FDA approved with a track record of over 80% effectiveness in patients. Up over 400% ytd and will continue to grow baby grow....
Recs
jpat34721
(22.11)
Submitted: 5/6/2014 2:32:35 PM :
Start Price:
$2.56
NYSE MKT:ISR Score:
-236.18
proprietary standard of care cancer therapy with proven results and expanding application.
Find the members with the highest scoring picks in ISR.
See what the Wall Street professionals think, according to their public statements and filings.
